Bionano Genomics, Inc. BNGO · NASDAQ
$1.22 +5.17% (+$0.06)
Summary
39 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Revenue growth is slowing: 0.8% a year over the last 3 years against 27% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 27% a year over 5 years. Over the last 3 years it grew by 0.8% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $32.2M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $46.5 is 3,711% above today's price. 57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 48%
- Consumable Revenue 25%
- Software Revenue 12%
- Instrument Revenue 12%
- Product and Service, Other 3.2%
By region
- EMEA 49%
- Americas 43%
- Asia Pacific 7.8%
Product brings in 48% of revenue. Product and Service, Other grew fastest, by 31% a year.
Segments in detail